FDA Hands MindMed’s LSD Candidate Breakthrough Therapy Designation in Generalised Anxiety Disorder; Company Provides 12-Week Data and Fleshes Out Phase 3 Program Plans – Psychedelic Alpha

Psychedelic drug developer MindMed today announced that the FDA has granted breakthrough therapy designation to its LSD candidate (MM120) for the treatment of generalised anxiety disorder (GAD). The company also shared topline 12-week data from the same program, as well as results of a pharmacokinetic bridging study and further details on phase 3 study design.

In this rapid response article:

• Fourth Breakthrough Therapy Designation for Psychedelics
• MindMed’s 12-Week Topline Data
• Looking Ahead to MM120’s Commercial Profile
• Next Steps (Phase 3 Program)

This article is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.